BR112022012230A2 - Variantes de progranulina - Google Patents
Variantes de progranulinaInfo
- Publication number
- BR112022012230A2 BR112022012230A2 BR112022012230A BR112022012230A BR112022012230A2 BR 112022012230 A2 BR112022012230 A2 BR 112022012230A2 BR 112022012230 A BR112022012230 A BR 112022012230A BR 112022012230 A BR112022012230 A BR 112022012230A BR 112022012230 A2 BR112022012230 A2 BR 112022012230A2
- Authority
- BR
- Brazil
- Prior art keywords
- progranulin
- variants
- proteins
- ftd
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
VARIANTES DE PROGRANULINA. A presente invenção refere-se a variantes de progranulina e proteínas de fusão que compreendem uma variante de progranulina e um polipeptídeo Fc. Métodos de uso de tais proteínas para tratar distúrbios associados à progranulina (por exemplo, uma doença neurodegenerativa, como demência frontotemporal (FTD)) também são fornecidos neste documento.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962953099P | 2019-12-23 | 2019-12-23 | |
US202063091819P | 2020-10-14 | 2020-10-14 | |
PCT/US2020/066831 WO2021133907A1 (en) | 2019-12-23 | 2020-12-23 | Progranulin variants |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022012230A2 true BR112022012230A2 (pt) | 2022-08-30 |
Family
ID=76437806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022012230A BR112022012230A2 (pt) | 2019-12-23 | 2020-12-23 | Variantes de progranulina |
Country Status (12)
Country | Link |
---|---|
US (4) | US20210188925A1 (pt) |
EP (1) | EP4081536A1 (pt) |
JP (1) | JP2023507846A (pt) |
KR (1) | KR20220130678A (pt) |
CN (1) | CN114981297A (pt) |
AU (1) | AU2020411480B2 (pt) |
BR (1) | BR112022012230A2 (pt) |
CA (1) | CA3165846A1 (pt) |
CO (1) | CO2022008648A2 (pt) |
IL (1) | IL293994A (pt) |
MX (1) | MX2022007486A (pt) |
PE (1) | PE20230036A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018221731C1 (en) | 2017-02-17 | 2021-11-18 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
KR20220130678A (ko) | 2019-12-23 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 프로그라눌린 변이체들 |
PE20231931A1 (es) | 2020-10-14 | 2023-12-01 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas |
CN116121306A (zh) * | 2023-03-27 | 2023-05-16 | 迦进生物医药(上海)有限公司 | 一种human TfR1高表达的稳转细胞株及其构建方法和应用 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040110938A1 (en) | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
CA2449412C (en) | 2000-11-30 | 2013-04-02 | Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
EP2292271A3 (en) | 2001-10-10 | 2011-09-14 | BioGeneriX AG | Remodelling and glycoconjugation of an antibody |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US20050123962A1 (en) | 2003-10-28 | 2005-06-09 | Agy Therapeutics, Inc. | Regulated nucleic acids in pathogenesis of alzheimer's disease |
EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
CN101098891B (zh) | 2005-01-05 | 2014-05-21 | F-星生物技术研究与开发有限公司 | 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域 |
CA2653974A1 (en) | 2006-05-30 | 2008-02-14 | Mayo Foundation For Medical Education And Research | Detecting and treating dementia |
EP2687223B1 (en) | 2006-05-30 | 2017-07-12 | Mayo Foundation For Medical Education And Research | Detecting and treating dementia |
CN101460621B (zh) | 2006-06-07 | 2016-01-27 | 建新公司 | 肌萎缩性侧索硬化和其他脊髓失调症的基因治疗 |
US7928068B2 (en) | 2007-01-31 | 2011-04-19 | New York University | Methods for using GEP, a chondrogenic growth factor and target in cartilage disorders |
DE102007033359B4 (de) | 2007-07-16 | 2010-12-02 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Verwendung eines Granulins oder einer Granulin-ähnlichen Verbindung zur Therapie oder Prophylaxe von chronischen Schmerzen |
US20100324127A1 (en) | 2008-01-16 | 2010-12-23 | Kay Denis G | Treating neurodegenerative diseases with progranulin |
WO2010022175A1 (en) | 2008-08-19 | 2010-02-25 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
CN102724993B (zh) | 2009-04-17 | 2016-04-27 | 纽约大学 | 靶向tnf家族受体并拮抗tnf作用的肽、组合物、方法及其用途 |
JP6312436B2 (ja) | 2010-11-16 | 2018-04-18 | ニューロダイン ライフ サイエンシズ インコーポレイテッドNeurodyn Life Sciences Inc. | ネプリライシンの発現および活性を増大させるための方法および医薬組成物 |
KR102099462B1 (ko) | 2010-11-30 | 2020-04-10 | 제넨테크, 인크. | 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도 |
CA2825064C (en) | 2011-02-04 | 2022-08-30 | Genentech, Inc. | Fc variants and methods for their production |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
EA201791693A1 (ru) | 2011-03-25 | 2018-05-31 | Гленмарк Фармасьютикалс С.А. | Гетеродимерные иммуноглобулины |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
CA2859755C (en) | 2011-12-23 | 2021-04-20 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
BR112014026162A2 (pt) | 2012-04-23 | 2017-10-03 | Nrl Pharma Inc | Proteína de fusão ou variante da mesma, molécula de ácido nucleico, vetor de expressão, célula hospedeira, animal não humano geneticamente modificado, planta geneticamente modificada, agente terapêutico para doenças melhoradas por lactoferrina, composição farmacêutica, e, método para preparar a proteína de fusão ou variante da mesma |
RS58928B1 (sr) | 2012-08-29 | 2019-08-30 | Hoffmann La Roche | Transporter za krvno-moždanu barijeru |
US9951145B2 (en) | 2012-11-27 | 2018-04-24 | Ajou University Industry—Academic Cooperation Foundation | CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
JP2016501881A (ja) | 2012-12-04 | 2016-01-21 | アッヴィ・インコーポレイテッド | 血液脳関門(bbb)を透過する二重特異性結合タンパク質 |
WO2014185964A1 (en) | 2013-05-14 | 2014-11-20 | California Institute Of Technology | Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier |
WO2014189973A2 (en) | 2013-05-20 | 2014-11-27 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
KR20230073341A (ko) | 2013-07-05 | 2023-05-25 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
LT3027642T (lt) | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
WO2015024931A1 (en) | 2013-08-19 | 2015-02-26 | Moghimi Seyed Moien | Peptidic nanodelivery composition targeting two receptors |
CA2938577A1 (en) | 2014-02-04 | 2015-08-13 | New York University | Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases |
CN105273087A (zh) * | 2014-07-14 | 2016-01-27 | 复旦大学 | NGF-Fc融合蛋白及其制备方法 |
EP3218411B1 (en) | 2014-11-14 | 2022-01-12 | Ossianix, Inc. | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use |
JP6779876B2 (ja) | 2014-11-19 | 2020-11-04 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
JP6993228B2 (ja) | 2014-11-19 | 2022-03-03 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法 |
MX2017006626A (es) | 2014-11-20 | 2017-08-21 | Hoffmann La Roche | Cadenas ligeras comunes y metodos de uso. |
CN114409783A (zh) | 2015-06-24 | 2022-04-29 | Jcr制药股份有限公司 | 通过血脑屏障的抗人转铁蛋白受体抗体 |
HRP20220304T1 (hr) | 2015-06-24 | 2022-05-13 | F. Hoffmann - La Roche Ag | Anti-transferinska receptorska protutijela s prilagođenim afinitetom |
WO2016207091A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use |
US11390656B2 (en) | 2015-08-04 | 2022-07-19 | New York University | Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases |
JP6932700B2 (ja) | 2015-09-15 | 2021-09-08 | アムジエン・インコーポレーテツド | 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
WO2018013775A2 (en) | 2016-07-14 | 2018-01-18 | Emory University | Granulin compositions and uses related thereto |
AR110586A1 (es) | 2016-12-26 | 2019-04-10 | Japan Chem Res | Anticuerpo de receptor antitransferrina humana que penetra la barrera hematoencefálica |
US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
AU2018221731C1 (en) | 2017-02-17 | 2021-11-18 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
CN110520440A (zh) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | 抗τ抗体及其使用方法 |
LT3665192T (lt) | 2017-08-10 | 2023-10-25 | Denali Therapeutics Inc. | Inžineriniu būdu sukurti transferino receptorių surišantys polipeptidai |
MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
BR112020013921A2 (pt) | 2018-01-10 | 2020-12-01 | Denali Therapeutics Inc. | polipeptídeos de ligação ao receptor de transferrina e usos destes |
KR102204521B1 (ko) | 2018-04-17 | 2021-01-20 | 한국생명공학연구원 | Progranulin 단백질을 포함하는 간질환의 예방 또는 치료용 조성물 |
MX2020012518A (es) | 2018-06-18 | 2021-02-16 | Denali Therapeutics Inc | Proteinas de fusion que comprenden progranulina. |
WO2020037150A2 (en) | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
SG11202101436SA (en) | 2018-08-22 | 2021-03-30 | Denali Therapeutics Inc | Anti-her2 polypeptides and methods of use thereof |
EP3866861A4 (en) | 2018-10-16 | 2022-09-07 | Denali Therapeutics Inc. | METHODS OF TREATMENT AND MONITORING OF PROGRANULIN-ASSOCIATED DISEASES |
US20220025065A1 (en) | 2018-12-10 | 2022-01-27 | Denali Therapeutics Inc. | Lysosomal storage disorder biomarkers and methods of use thereof |
KR20220004651A (ko) | 2019-04-03 | 2022-01-11 | 데날리 테라퓨틱스 인크. | 이두로네이트 2-설파타제를 포함하는 단백질 분자의 제제 |
KR20220130678A (ko) | 2019-12-23 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 프로그라눌린 변이체들 |
BR112022013756A2 (pt) | 2020-01-13 | 2022-10-11 | Denali Therapeutics Inc | Anticorpos anti-trem2 e métodos de uso dos mesmos |
CN115698037A (zh) | 2020-02-07 | 2023-02-03 | 戴纳立制药公司 | 用于治疗亨特综合征的方法 |
WO2022082178A2 (en) | 2020-10-14 | 2022-04-21 | Denali Therapeutics Inc. | Methods for treating and monitoring frontotemporal dementia |
PE20231931A1 (es) | 2020-10-14 | 2023-12-01 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas |
-
2020
- 2020-12-23 KR KR1020227022284A patent/KR20220130678A/ko unknown
- 2020-12-23 AU AU2020411480A patent/AU2020411480B2/en active Active
- 2020-12-23 CA CA3165846A patent/CA3165846A1/en active Pending
- 2020-12-23 MX MX2022007486A patent/MX2022007486A/es unknown
- 2020-12-23 EP EP20842153.7A patent/EP4081536A1/en active Pending
- 2020-12-23 PE PE2022001166A patent/PE20230036A1/es unknown
- 2020-12-23 JP JP2022538728A patent/JP2023507846A/ja active Pending
- 2020-12-23 CN CN202080089731.1A patent/CN114981297A/zh active Pending
- 2020-12-23 IL IL293994A patent/IL293994A/en unknown
- 2020-12-23 BR BR112022012230A patent/BR112022012230A2/pt unknown
-
2021
- 2021-01-26 US US17/159,038 patent/US20210188925A1/en not_active Abandoned
-
2022
- 2022-03-17 US US17/697,771 patent/US11643446B2/en active Active
- 2022-03-18 US US17/698,456 patent/US20220220172A1/en not_active Abandoned
- 2022-06-21 CO CONC2022/0008648A patent/CO2022008648A2/es unknown
-
2023
- 2023-03-24 US US18/189,413 patent/US20230265137A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2022007486A (es) | 2022-06-29 |
AU2020411480A1 (en) | 2022-06-30 |
CA3165846A1 (en) | 2021-07-01 |
US11643446B2 (en) | 2023-05-09 |
PE20230036A1 (es) | 2023-01-10 |
IL293994A (en) | 2022-08-01 |
US20230265137A1 (en) | 2023-08-24 |
CN114981297A (zh) | 2022-08-30 |
JP2023507846A (ja) | 2023-02-27 |
US20220220172A1 (en) | 2022-07-14 |
EP4081536A1 (en) | 2022-11-02 |
KR20220130678A (ko) | 2022-09-27 |
CO2022008648A2 (es) | 2022-06-30 |
AU2020411480B2 (en) | 2023-12-21 |
US20210188925A1 (en) | 2021-06-24 |
US20220213155A1 (en) | 2022-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022012230A2 (pt) | Variantes de progranulina | |
CL2020003255A1 (es) | Proteínas de fusión que comprenden progranulina | |
CO2018012096A2 (es) | Proteínas de fusión gdf15 y usos de estas | |
MX2022013526A (es) | Degradadores de proteinas y usos de los mismos. | |
DOP2019000241A (es) | ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
CL2020000483A1 (es) | Nuevos usos de derivados de piperidinil–indol. | |
BR112018011308A2 (pt) | anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos | |
CO2020009402A2 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
MX2020007628A (es) | Composiciones y metodos de uso. | |
BR112018072118A2 (pt) | anticorpos de interferona beta e usos dos mesmos | |
MX2020006635A (es) | Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma. | |
PH12020500054A1 (en) | Novel therapeutic enzyme fusion protein and use thereof | |
EA201691834A1 (ru) | Новый способ очистки гонадотропина | |
ECSP22049014A (es) | Variantes de progranulina | |
CL2020002507A1 (es) | Variantes de lfa3 y composiciones y usos de las mismas | |
CO2022002627A2 (es) | Composiciones biofarmacéuticas y procedimientos conexos | |
CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. | |
ECSP22019177A (es) | Proteínas de fusión nkg2d y sus usos | |
BR112022014160A2 (pt) | Fatores de transcrição de proteína dedo de zinco para reprimir a expressão de tau | |
AR115565A1 (es) | Proteínas de fusión que comprenden progranulina | |
EA202190062A1 (ru) | Слитые белки, содержащие програнулин | |
AR119984A1 (es) | Proteínas de fusión nkg2d y sus usos | |
EA202091111A1 (ru) | Модуляторы интегрированного стресса | |
AR119587A1 (es) | Composiciones biofarmacéuticas y procedimientos conexos | |
EA202092327A1 (ru) | Варианты lfa3 и их композиции и применение |